Carmed Pharmaceuticals Expands U.S. Distribution Through Curated Online Marketplace Launch

Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, announced plans to expand its U.S. distribution with an upcoming launch on OneLavi, a curated online marketplace for beauty, health, and wellness products. The planned launch represents another step in Carmed's U.S. expansion strategy, focused on increasing accessibility to its research-driven formulations while building long-term credibility in the American market. The OneLavi launch follows Carmed's previously announced plans to introduce its formulations on Amazon, reflecting a broader multi-channel approach to U.S. distribution.

The addition of OneLavi to Carmed's distribution strategy reflects the company's focus on reaching consumers through curated platforms that emphasize quality, transparency, and product discovery. Unlike broader marketplaces, OneLavi provides a more selective environment where brands are positioned alongside premium wellness offerings, allowing Carmed to introduce its formulations within a more focused consumer experience. "Expanding onto OneLavi allows us to introduce our formulations in a curated environment where quality and product integrity are prioritized," said Mustafa Can, Founder of Carmed Pharmaceuticals. "This aligns with our commitment to standardized development and consistent formulation quality."

As part of its OneLavi launch, Carmed Pharmaceuticals plans to introduce several of its core formulations including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, Vacrol-M® Capsule, and Omevaq-3®. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. According to the company, all formulations are developed using standardized processes designed to ensure consistency, reproducibility, and quality control across production.

Carmed's formulation approach is supported by ongoing collaboration with academic institutions, laboratories, and medical researchers focused on bioactive compounds and formulation science. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models, contributing to the broader scientific investigation of carvacrol-based formulations and multicomponent botanical interactions. The company emphasizes that this research reflects scientific investigation into formulation science and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

Carmed states that its U.S. strategy is centered on expanding availability across both large-scale and curated retail platforms while maintaining alignment with regulatory standards and long-term scientific positioning. "The OneLavi launch is an important step in building awareness and accessibility for Carmed in the United States," said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. "We are focused on introducing our formulations to new audiences while maintaining the same standards of quality, consistency, and research-driven development." Availability timelines and product listings on OneLavi will be announced in the coming weeks.